|
|
 |
|
Viewing report
|
|
|
|
Actelion Ltd: PharmaVitae Report
Datamonitor, Oct 2011, Pages: 56
This analysis examines the historical and forecast performance for Actelion in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Actelion's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
With further PAH launches anticipated, most notably macitentan, which is expected to launch before Tracleer’s US patent expiry in 2015, Actelion’s outlook is overall positive.
Your key questions answered
- Benchmark Actelion's performance against key rivals in the prescription pharmaceutical sector
- Assess the strategies undertaken by Actelion to become the dominant force in the PAH market
- Determine how Actelion will overcome the clinical failure of almorexant
- Determine the measures Actelion will put in place in order to protect its PAH market share fromTracleer's 2015 expiry
|
|
|
|
